Arcosa (ACA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Mar, 2026Executive summary
Annual meeting scheduled for May 13, 2026, with virtual attendance available for shareholders.
Shareholders are encouraged to review proxy materials and vote by May 12, 2026.
Voting matters and shareholder proposals
Election of nine directors to the board is up for shareholder vote.
Advisory vote on executive compensation (say-on-pay) is included.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Board recommends voting in favor of all proposals.
Board of directors and corporate governance
Nine nominees are presented for election to the board, including Joseph Alvarado, Rhys J. Best, Antonio Carrillo, Jeffrey A. Craig, Steven J. Demetriou, John W. Lindsay, Kimberly S. Lubel, Julie A. Piggott, and Melanie M. Trent.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Arcosa
- CRH’s $8.5B acquisition of Arcosa offers a 25% premium and accelerates infrastructure growth.ACA
Proxy filing22 Jun 2026 - Arcosa to be acquired by CRH for $8.5B, with shareholders receiving $150 per share.ACA
Proxy filing22 Jun 2026 - Definitive agreement for acquisition by CRH announced, pending shareholder approval in Q1 2027.ACA
Proxy filing22 Jun 2026 - Agreement reached for $8.5B acquisition by CRH, pending shareholder approval.ACA
Proxy filing22 Jun 2026 - CRH Americas to acquire Arcosa for $8.5B in cash, strengthening its U.S. infrastructure leadership.ACA
Proxy filing22 Jun 2026 - Streamlined portfolio and raised 2026 outlook driven by strong infrastructure demand.ACA
Investor presentation8 Jun 2026 - Q1 2026 Adjusted EBITDA up 10%, guidance raised, and barge divestiture boosted liquidity.ACA
Q1 20261 May 2026 - Record financial results, strong governance, and sustainability milestones highlighted.ACA
Proxy filing31 Mar 2026 - Record 2025 growth, barge divestiture, and strong 2026 EBITDA outlook with margin expansion.ACA
Q4 202527 Feb 2026